Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) was $434.03 for the day, down -0.30% from the previous closing price of $435.32. In other words, the price has decreased by -$0.30 from its previous closing price. On the day, 1.62 million shares were traded.
Ratios:
Our analysis of VRTX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.29 and its Current Ratio is at 2.65. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.10.
On May 06, 2025, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform but kept the price unchanged to $503.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 21 ’25 when LR 2019 Benefit Trust bought 170 shares for $447.18 per share.
SR 2019 Benefit Trust bought 170 shares of VRTX for $76,021 on May 21 ’25. On May 15 ’25, another insider, ALTSHULER DAVID, who serves as the EVP, Chief Scientific Officer of the company, sold 52 shares for $424.69 each. As a result, the insider received 22,084 and left with 23,281 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 10.09 while its Price-to-Book (P/B) ratio in mrq is 6.76.
Stock Price History:
Over the past 52 weeks, VRTX has reached a high of $519.88, while it has fallen to a 52-week low of $377.85. The 50-Day Moving Average of the stock is -9.45%, while the 200-Day Moving Average is calculated to be -7.22%.
Shares Statistics:
A total of 256.97M shares are outstanding, with a floating share count of 256.00M. Insiders hold about 0.31% of the company’s shares, while institutions hold 94.78% stake in the company.
Earnings Estimates
The dynamic stock of Vertex Pharmaceuticals, Inc (VRTX) is currently being evaluated by a team of 24.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is $4.6, with high estimates of $4.9 and low estimates of $4.0.
Analysts are recommending an EPS of between $18.79 and $17.19 for the fiscal current year, implying an average EPS of $18.0. EPS for the following year is $20.66, with 26.0 analysts recommending between $26.71 and $16.56.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 26 analysts. It ranges from a high estimate of $3.01B to a low estimate of $2.8B. As of the current estimate, Vertex Pharmaceuticals, Inc’s year-ago sales were $2.65BFor the next quarter, 26 analysts are estimating revenue of $3.05B. There is a high estimate of $3.13B for the next quarter, whereas the lowest estimate is $2.98B.
A total of 32 analysts have provided revenue estimates for VRTX’s current fiscal year. The highest revenue estimate was $12.25B, while the lowest revenue estimate was $11.75B, resulting in an average revenue estimate of $11.94B. In the same quarter a year ago, actual revenue was $11.02BBased on 29 analysts’ estimates, the company’s revenue will be $13.26B in the next fiscal year. The high estimate is $14.95B and the low estimate is $11.94B.
